- Home
- ORGO vs DAWN Comparison
ORGO vs DAWN Comparison
Compare ORGO & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORGO
- DAWN
- Stock Information
- Founded
- ORGO 1985
- DAWN 2018
- Country
- ORGO United States
- DAWN United States
- Employees
- ORGO N/A
- DAWN N/A
- Industry
- ORGO Biotechnology: Pharmaceutical Preparations
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- ORGO Health Care
- DAWN Health Care
- Exchange
- ORGO Nasdaq
- DAWN Nasdaq
- Market Cap
- ORGO 620.3M
- DAWN 624.8M
- IPO Year
- ORGO N/A
- DAWN 2021
- Fundamental
- Price
- ORGO $4.92
- DAWN $7.19
- Analyst Decision
- ORGO Buy
- DAWN Strong Buy
- Analyst Count
- ORGO 2
- DAWN 7
- Target Price
- ORGO $7.50
- DAWN $27.86
- AVG Volume (30 Days)
- ORGO 729.3K
- DAWN 1.1M
- Earning Date
- ORGO 11-11-2025
- DAWN 10-29-2025
- Dividend Yield
- ORGO N/A
- DAWN N/A
- EPS Growth
- ORGO N/A
- DAWN N/A
- EPS
- ORGO N/A
- DAWN N/A
- Revenue
- ORGO $429,531,000.00
- DAWN $187,638,000.00
- Revenue This Year
- ORGO $2.57
- DAWN $12.56
- Revenue Next Year
- ORGO $9.80
- DAWN $48.02
- P/E Ratio
- ORGO N/A
- DAWN N/A
- Revenue Growth
- ORGO N/A
- DAWN 2190.50
- 52 Week Low
- ORGO $2.48
- DAWN $5.64
- 52 Week High
- ORGO $6.71
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- ORGO 54.02
- DAWN 52.01
- Support Level
- ORGO $4.75
- DAWN $7.18
- Resistance Level
- ORGO $5.10
- DAWN $7.58
- Average True Range (ATR)
- ORGO 0.21
- DAWN 0.27
- MACD
- ORGO -0.01
- DAWN -0.03
- Stochastic Oscillator
- ORGO 51.40
- DAWN 33.92
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.